Phase 2 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women aged 18 to 75 years
- People whose breast cancer has been confirmed by a tissue sample (biopsy) to be a type called HR-positive and HER2-low invasive breast cancer
- People who have not yet received any treatment for their breast cancer and whose cancer is at stage II or III
- People who are relatively active and able to carry out everyday activities, as measured by a standard health scoring system (a score of 0 or 1 on the ECOG scale)
- People whose major organs (such as the liver, kidneys, and heart) are functioning at a good level
- People who are willing to participate voluntarily, sign a consent form, follow the trial requirements, and attend follow-up visits
Who may not be able to join:
- People who have previously received any cancer treatment, such as chemotherapy, radiotherapy, targeted therapy, or hormone therapy
- People who are currently receiving any other cancer treatment at the same time as this trial
- People who have cancer in both breasts, inflammatory breast cancer, or a type where the cancer cannot be detected in the breast itself (occult breast cancer)
- People whose breast cancer has spread to other parts of the body (stage IV)
- People whose cancer has not been confirmed through a tissue sample (biopsy)
- People who have had any other type of cancer in the past 5 years, except for certain fully treated cancers such as early-stage cervical cancer or a specific type of skin cancer (non-melanoma skin cancer) (confirm with trial site)
- People who have taken part in another clinical drug trial within the 4 weeks before joining this trial
- People with a known allergy to any of the ingredients in the treatments used in this trial
- People with a history of a weakened immune system
- People with significant heart or blood vessel problems
- People with known or suspected lung disease affecting the tissue between the air sacs (interstitial lung disease)
- People with active hepatitis (liver infection) or liver cirrhosis (liver scarring)
- People with a known tendency to bleed or form blood clots, whether inherited or developed over time
- People with a history of neurological (brain or nerve) or psychiatric (mental health) conditions
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Caigang Liu, MD, Shengjing Hospital
Phone: 86-18940256668
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Total pathological complete response (tpCR: ypT0-is/ypN0)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.